Abstract:Background: The accumulation of β-amyloid (Aβ) peptides into insoluble plaques is an early pathological feature of Alzheimer's disease (AD). BACE1 is the sole β-secretase for Aβ generation, making it an attractive therapeutic target for AD therapy. While BACE1 inhibitors have been shown to reduce Aβ levels in people with AD, clinical trials targeting BACE1 have failed due to unwanted synaptic deficits. Understanding the physiological role of BACE1 in individual cell types is essential for developing effective BACE inhibitors for the treatment of AD. Recent single-cell RNA transcriptomic assays revealed that oligodendrocytes are enriched with genes required for generating Aβ. However, the contribution of oligodendrocytes to amyloid plaque burden in AD and the side effects of oligodendrocyte-specific Bace1 deletion remain to be explored. Methods: We generated an oligodendrocyte-specific Bace1 knockout model (Bace1fl/fl;Olig2-Cre) to monitor potential disruptions in myelination using standard electron microscopy. Long-term potentiation (LTP) was monitored to measure synaptic integrity. We crossed the Bace1fl/fl;Olig2-Cre model with heterozygous AppNL-G-F/wt knock-in AD mice to generate AD mice lacking oligodendrocyte Bace1 (Bace1fl/fl;Olig2-Cre; AppNL-G-F/wt) and examined amyloid plaque number and insoluble Aβ levels and gliosis in these animals. Single nuclei RNA sequencing experiments were conducted to examine molecular changes in response to Bace1 deficiency in oligodendrocytes in the wild type or APP knock-in background. Results: Bace1 deletion in oligodendrocytes caused no change in myelin thickness in the corpus callosum but a marginal reduction in myelin sheath thickness of the optic nerve. Synaptic strength measured by LTP was not different between Bace1fl/fl;Olig2-Cre and age-matched Bace1fl/fl control animals, suggesting no major effect on synaptic plasticity. Intriguingly, deletion of Bace1 in 12-month-old heterozygous AD knock-in mice (Bace1fl/fl;Olig2-Cre; AppNL-G-F/wt mice) caused a significant reduction of amyloid plaques by ~ 33% in the hippocampus and ~ 29% in the cortex compared to age-matched AD mice (Bace1fl/fl;AppNL-G-F/wt). Insoluble Aβ1-40 and Aβ1-42 levels were reduced comparably while more astrocytes and microglia were observed in surrounding amyloid plaques. Unbiased single-nuclei RNA sequencing results revealed that deletion of oligodendrocyte Bace1 in APPNL-G-F/wt knock-in mice increased expression of genes associated with Aβ generation and clearance such as ADAM10, Ano4, ApoE, Il33, and Sort1. Conclusion: Our results provide compelling evidence that the amyloidogenic pathway in oligodendrocytes contributes to Aβ plaque formation in the AD brain. While specifically targeting BACE1 inhibition in oligodendrocytes for reducing Aβ pathology in AD is likely challenging, this is a potentially explorable strategy in future studies.

Beta Secretase Localization, Amyloid Deposition And Aberrant Synaptic And Neuritic Sprouting In Transgenic Mouse Alzheimer Models: A Role For Bace1 In Synaptic Remodeling And Plaque Formation?

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

A Novel Role Of Beta-Secretase 1 (Bace1) In The Pathogenesis Of Cerebral Amyloid Angiopathy (Caa)

O4‐02‐01: A Novel Role of Beta‐secretase1 (BACE1) in the Pathogenesis of Cerebral Amyloid Angiopathy (CAA)

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

Spatiotemporal Activation Of The C/Ebp Beta/Delta-Secretase Axis Regulates The Pathogenesis Of Alzheimer'S Disease

Alzheimer's Β-Secretase (BACE1) Regulates the Camp/pka/creb Pathway Independently of Β-Amyloid.

Neurodegenerative Changes Associated with β-Amyloid Deposition in the Brains of Mice Carrying Mutant Amyloid Precursor Protein and Mutant Presenilin-1 Transgenes

The Effect of Chronic Cerebral Hypoperfusion on Amyloid-β Metabolism in a Transgenic Mouse Model of Alzheimer's Disease (PS1V97L).

BAG-1M Co-Activates BACE1 Transcription Through NF-κB and Accelerates Aβ Production and Memory Deficit in Alzheimer's Disease Mouse Model.

Aβ Amyloid Scaffolds the Accumulation of Matrisome and Additional Proteins in Alzheimer's Disease

BACE1 controls synaptic function through modulating release of synaptic vesicles

Contribution of amyloid deposition from oligodendrocytes in a mouse model of Alzheimer's disease

Lys203 and Lys382 Are Essential for the Proteasomal Degradation of BACE1

β-Secretase 1’s Targeting Reduces Hyperphosphorilated Tau, Implying Autophagy Actors in 3xTg-AD Mice

O1–08–02: Cathepsin B Produces Brain Pyro‐glu‐beta‐amyloid in a Transgenic Alzheimer's Disease Mouse Model

A GPCR/secretase Complex Regulates Β- and Γ-Secretase Specificity for Aβ Production and Contributes to AD Pathogenesis

The Alzheimer's β-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb

Amyloid Accumulation Drives Proteome-wide Alterations in Mouse Models of Alzheimer's Disease-like Pathology

BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time

APP β-CTF triggers cell-autonomous synaptic toxicity independent of Aβ